Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein

作者: Florian Klein , Christian Gaebler , Hugo Mouquet , D. Noah Sather , Clara Lehmann

DOI: 10.1084/JEM.20120423

关键词:

摘要: Two to three years after infection, a fraction of HIV-1–infected individuals develop serologic activity that neutralizes most viral isolates. Broadly neutralizing antibodies recognize the HIV-1 envelope protein have been isolated from these patients by single-cell sorting and neutralization screens. Here, we report new method for anti–HIV-1 antibody isolation based on capturing single B cells expressed surface transfected cells. Although far less efficient than soluble baits, cell-based capture identified bind broadly epitope in vicinity V3 loop CD4-induced site (CD4i). The is cell form spike, but not forms same protein. Moreover, complement spectrum potent anti-CD4 binding (CD4bs) obtained individual. Thus, combinations with complementary can account breadth potency naturally arising activity. Therefore, vaccines aimed at eliciting should be limited epitopes.

参考文章(58)
Yan Liu, Robert A. Childs, Angelina S. Palma, Maria A. Campanero-Rhodes, Mark S. Stoll, Wengang Chai, Ten Feizi, Neoglycolipid-based oligosaccharide microarray system: preparation of NGLs and their noncovalent immobilization on nitrocellulose-coated glass slides for microarray analyses. Methods of Molecular Biology. ,vol. 808, pp. 117- 136 ,(2012) , 10.1007/978-1-61779-373-8_8
John R. Mascola, Gabriela Stiegler, Thomas C. VanCott, Hermann Katinger, Calvin B. Carpenter, Chris E. Hanson, Holly Beary, Deborah Hayes, Sarah S. Frankel, Deborah L. Birx, Mark G. Lewis, Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies Nature Medicine. ,vol. 6, pp. 207- 210 ,(2000) , 10.1038/72318
T Muster, F Steindl, M Purtscher, A Trkola, A Klima, G Himmler, F Rüker, H Katinger, A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Journal of Virology. ,vol. 67, pp. 6642- 6647 ,(1993) , 10.1128/JVI.67.11.6642-6647.1993
A Trkola, M Purtscher, T Muster, C Ballaun, A Buchacher, N Sullivan, K Srinivasan, J Sodroski, J P Moore, H Katinger, Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of Virology. ,vol. 70, pp. 1100- 1108 ,(1996) , 10.1128/JVI.70.2.1100-1108.1996
Leonidas Stamatatos, Lynn Morris, Dennis R Burton, John R Mascola, Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nature Medicine. ,vol. 15, pp. 866- 870 ,(2009) , 10.1038/NM.1949
Jan Albert, Bengt Abrahamsson, Karoly Nagy, Elisabeth Aurelius, Hans Gaines, Gunnel Nyström, Eva Maria Fenyö, Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS. ,vol. 4, pp. 107- 112 ,(1990) , 10.1097/00002030-199002000-00002
Iliyana Mikell, D. Noah Sather, Spyros A. Kalams, Marcus Altfeld, Galit Alter, Leonidas Stamatatos, Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 PLoS Pathogens. ,vol. 7, pp. e1001251- ,(2011) , 10.1371/JOURNAL.PPAT.1001251
Hugo Mouquet, Johannes F. Scheid, Markus J. Zoller, Michelle Krogsgaard, Rene G. Ott, Shetha Shukair, Maxim N. Artyomov, John Pietzsch, Mark Connors, Florencia Pereyra, Bruce D. Walker, David D. Ho, Patrick C. Wilson, Michael S. Seaman, Herman N. Eisen, Arup K. Chakraborty, Thomas J. Hope, Jeffrey V. Ravetch, Hedda Wardemann, Michel C. Nussenzweig, Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation Nature. ,vol. 467, pp. 591- 595 ,(2010) , 10.1038/NATURE09385
Ann J. Hessell, Eva G. Rakasz, Pascal Poignard, Lars Hangartner, Gary Landucci, Donald N. Forthal, Wayne C. Koff, David I. Watkins, Dennis R. Burton, Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers PLOS Pathogens. ,vol. 5, ,(2009) , 10.1371/JOURNAL.PPAT.1000433